The reliability of a recently released total bilirubin assay for a blood gas analyser was assessed in two Australian hospital laboratories. The instrument computes total bilirubin concentration from multi-wavelength absorbance measurements of undiluted whole blood or plasma. Performance of the Radiometer ABL 735 blood gas analyser bilirubin method (software version 3.6) was compared with a proven Roche diazo method for Hitachi analysers, calibrated using primary standards prepared from NIST SRM 916a bilirubin. Acceptable bilirubin results were found over a wide concentration range for most neonatal samples of whole blood or plasma. For adult specimens, bilirubin results were approximately 10% lower on the blood gas analyser. Within-run imprecision (whole blood) was <2'5%, between-day imprecision (synthetic controls) < 1,0%, and the bilirubin assay for both whole blood and plasma was linear to 1000pmol/L. Using sampling options from 35 J.lL to 195pL, bilirubin results differed by less than 3%, with a 95 ilL syringe option producing the highest results. We conclude that the Radiometer ABL 735 bilirubin assay is suitable for near-patient assessment of neonatal jaundice using whole blood, thus eliminating the need for sample centrifugation. Verification using laboratory methods can be used when required. A positive correction of approximately 10% is required for adult specimens to conform with Hitachi results (SRM 916a calibration), possibly due to the optical characteristics of the higher proportion of conjugated bilirubin and other substances present in most adult samples.
INTRODUCTION
Although transcutaneous bilirubinometry can be used to screen for hyperbilirubinaemia, the severity of neonatal jaundice is usually assessed using serum or plasma in the routine diagnostic laboratory. \,2 Radiometer Copenhagen has recently developed a bilirubin method for a blood gas analyser which is convenient for near-patient testing and avoids the need to centrifuge blood.' In the assay, which can use routine blood gas samples (capillary or syringe), multiple absorbance measurements are made on whole blood (or plasma) over 128 wavelengths between 478 and 672nm. Opaque red cells are haemolysed in the blood gas analyser oximeter by ultrasonic vibration, which destroys the cell wall and releases haemoglobin. An accurate absorbance spectrum can then be measured on an optically clear haemolysate using a flowcell with a path length of only 0·1 mm. Because bilirubin is not present within erythrocytes, plasma bilirubin concentration is determined after the instrument calculates a dilution factor based on the haematocrit of the sample to correct for intracellular fluid released during red cell lysis.
Total bilirubin concentration is then computed after correcting for the various pigments present in either adult or foetal blood. Because adult and foetal haemoglobin (HbF) have different absorbance spectra, the instrument provides an option to correct (or not correct) for HbF concentrations <20%, depending on whether accuracy or precision is the more important criterion. Above 20%, correction for foetal haemoglobin is automatic.
The blood gas analyser is calibrated to provide total bilirubin results that are in close agreement with a proven laboratory method, the Roche DPD (2,5- 6 For 50 neonates with bilirubin concentrations between 110 and 400 j.lmoI/L, the Hitachi DPD method averaged 2·2% lower than the reference method of Doumas et al. 4 Gourley et al.' have also demonstrated that the Hitachi DPD method compares well with high-performance liquid chromatography (HPLC). For 944 neonates, the following relationship was found versus HPLC:
The standard deviation of points around the regression line (Sy.x) was 8·8j.lmol/L. 6 Thus, the Hitachi total bilirubin method provides a satisfactory, small sample volume, routine method for assessing the reliability of the blood gas analyser bilirubin method, with haemolysis less than 5 g/L HbF causing less than 5% negative interference with Hitachi results. 5.6 In late 1999, we were invited by Radiometer Copenhagen to assess their novel whole blood bilirubin method; the invitation was also extended to the Royal Brisbane Hospital. Following modifications to overcome a positive bias at high concentrations and a negative bias at low concentrations, we then evaluated an improved method, and our findings are the subject of the current paper.
MATERIALS AND METHODS
Total bilirubin measurements were made on a Radiometer ABL 735 blood gas analyser bilirubin module (software version 3.6) supplied by Radiometer Pacific Pty Ltd, Melbourne, Vic, Australia. Aliquots of heparinized whole blood and plasma for routine laboratory testing were assayed through the ABL 735 when sufficient sample volume was available. Radiometer blood gas syringes were used to collect some samples. Plasma samples (haemolysis < I g/L for adults and < 5 g/L for neonates) were also assayed using a Roche Hitachi 917 at the Flinders Ann Clin Biochem 2001: 38 Medical Centre (FMC) and through either a Roche Hitachi 917 or 747 at the Royal North Shore Hospital (RNSH). All specimens were protected from light and usually assayed within an hour of collection. The Hitachi DPD method was used exactly as recommended by Roche, and all results were 'back-calculated' against a set of bilirubin standards supplied by Radiometer Copenhagen, prepared as recommended by Doumas et al. from NIST SRM 916a. 4 The concentrations of these standards were 0, 33'7, /76·1 and 352·4 j.lmoI/L, and the accuracy of the standards was confirmed by independent preparation by the authors of another primary standard from the same material. All standards were stored at -70°C during the study.
Heparinized whole blood was used for both within-run precision studies and to check the influence of different ABL 735 sampling options on results. Radiometer Qualicheck controls (four levels) were used for between-day precision studies on the ABL 735.
Linearity was determined using whole blood supplemented with bilirubin, prepared according to Glick et al. 8 After analysing these linearly related samples on the ABL 735, plasma samples were prepared and analysed through both the ABL 735 and the Hitachi analysers, Statistical analyses were performed using the statistical package "Analyse-it for Microsoft Excel" (clinical laboratory version 1.61, Leeds, UK). Passing-Bablok linear regression calculations 9 • lo and Bland-Altman difference plots!' were used for data evaluation.
RESULTS

Precision
Within-run and between-day precision data are summarized in Table I . Within-run precision was assessed on the ABL 735 by assaying 20 aliquots of whole blood using 55 j.lL capillaries. Results ranged from 80 to 91 j.lmol/L for one sample [coefficient of variation (CV) = 2,5%] and 127 to 137j.lmol/L for another sample (CV = 2'0%). At higher concentrations of bilirubin, within-run precision was tested by assaying paired duplicates of whole blood samples with bilirubin concentrations in the range 200 to 300 j.lmol/L. CVs of around 2% were found, independent of sampling option. (s = standard deviation; d= difference between duplicates; n = number of duplicates).
Between-day precision was assessed using ampoules of Radiometer Qualicheck precision controls. CVs < 1·0% were obtained for all the bilirubin concentrations tested. Although these are synthetic solutions containing a dye that mimics bilirubin, the precision is such that any change in mean value for these control materials provides a reliable indication of drift in the bilirubin assay.
The mean bilirubin concentrations obtained for all four levels of control material were within I /lmol/L of the mean of the Radiometer target range at FMC, and within 4/lmol/L at RNSH, indicating that the bilirubin modules were working to the specifications established by Radiometer on both analysers.
Method correlation
Method correlation data are shown in Fig. I . For 97 neonatal heparinized blood samples assayed on the blood gas bilirubin module, 95% of results were within 25/lmo1/L of the Hitachi method at one laboratory (see Fig. la and Ib). The two lowest results had a slightly negative reduced haemoglobin percentage, which may indicate an atypical spectrum. For 52 neonatal heparinized blood samples assayed at the second laboratory, the 95% confidence limits for the differences in results were slightly larger, and the blood gas analyser bilirubin results were marginally lower (y=0·96Ix-6·2JlmoI/L)(see Fig. Ic ). The mean difference between methods was 10/lmol/L lower in the second laboratory, with 95% of results within 35 Jlmoi/L of the Hitachi method (see Fig.ld ).
Figures Ie and If indicate that the difference between the Hitachi and blood gas analyser bilirubin results is less for plasma than for whole blood (95% of results within 15/lmoI/L). This is not unexpected, as plasma has a less complex spectrum than whole blood. In addition, whole blood bilirubin measurements must be corrected for haematocrit, which is calculated from a representative MCHC of 332 g/L, (Radiometer advise that this can vary from 320 to 340 giL for neonates.)
For adults, data in Fig that bilirubin concentrations measured on the ABL 735 will be lower than those measured on the Hitachi by approximately 10%. Thus, the ABL 735 provides only a semi-quantitative assessment of adult bilirubin concentrations with the current software version, although a good approximation of an Hitachi bilirubin concentration can be made using the regression equation in Fig. l g, This approach is only useful for raised concentrations of bilirubin, due to the variability in results at low bilirubin concentrations on the ABL 735.
Whole blood versus plasma on the ABL 735
For neonates, 95% of matched plasma (x) and whole blood (y) bilirubin results agreed within 20 }Jmol/L on the ABL 735 bilirubin module: For adults, 95% agreement was within I5llmol/L for the range of concentrations tested, although the heparinized blood results were lower than the plasma results at high concentrations: y = Q·949x + l: 3 jlIDol/L, n = 55 (graphs not shown).
Interferences
During early studies, one laboratory (RNSH) observed that samples collected in EDT A produced bilirubin results on the ABL 735 that were approximately 30% lower than those for samples collected in lithium heparin, possibly due to spectrum alterations for whole blood. At the present time, EDTA samples are not recommended for ABL 735 bilirubin measurements.
In the adult comparison studies, one patient had falsely high results for whole blood bilirubin on the ABL 735 (duplicate bilirubin = 96 and IOlllmol/L) compared with the plasma result on the ABL 735 (46Ilmol/L) or on the Hitachi 917 (51 and 5lllmol/L). This sample also had a foetal haemoglobin reading of 73% and a negative carboxyhaemoglobin level (-1.5%). This patient had previously been given Haemocell (Chiron Behring, Marberg, Germany), an artificial volume expander. Later samples from this patient continued to show these abnormalities, with the difference between plasma and whole blood bilirubin results on the ABL 735 gradually disappearing 3 weeks after Haemocell infusion. Although no error messages were given on the ABL 735 for these samples, it appears that Haemocell may cause an atypical spectrum which compromises bilirubin results. Radiometer have noted that methylene blue and some other substances may also cause optical interference.
Linearity and measuring range
The linearity of the ABL 735 bilirubin assay was assessed using whole blood and plasma to which bilirubin had been added.
From these experiments, the assay was shown to be linear to at least 1000JlmoljL. Thus, bilirubin measurements up to 1000Jlmol/L are in the measuring range of the blood gas analyser, using either whole blood or plasma as the sample medium.
Sampling options
The ABL 735 may be used in either a 'micro' or 'macro' mode, depending on sample availability. In a micro mode, the sample moves in two stages through the blood gas and oximeter measuring chambers. In a macro mode, the sample fills both chambers simultaneously. Capillary or syringe samples may be used in either micro or macro modes.
To determine whether the sampling mode had any significant influence on results, four replicate measurements of bilirubin concentration were made using four different sampling modes (capillary, 35 JlL and 55JlL; syringe, 95 JlL and 195JlL). The mean (± 2 standard error of the mean) bilirubin results for each option were 149·5±0·6, 151·3±2·6, 155·0± 1·4 and 150·8± 2·5Jlmol/L respectively, with the 95JlL syringe results being slightly higher than the other options.
We also assayed II whole blood samples in duplicate, with bilirubin concentrations ranging from 30 to 300Jlmol/L, using all of the above sampling options, and the average bias found for each sampling option was consistent with that found for the quadruplicates above. Occasional variations in bilirubin results, up to 20 Jlmol/L, were found for single assays of the same sample using alJ four sampling options at high concentrations of bilirubin.
Difference (ABL 735 -Hitachi) versus POl' pH, HbF and Het For samples of neonatal whole blood [pH 7,18--+7,61, pOz 25--+250mmHg, HbF 10--+ 100% and haematocrit (Hct) 25 --+ 68%], there was no significant linear dependency between each variable and the bias between Hitachi and ABL 735 bilirubin results. In each case, the P levels calculated using Analyse-it exceeded the critical level for dependency (P<0'05) and the correlation coefficients were smalJ (for pH, pOz, HbF and Hct, P=0'36, 0,57, 0·17 and 0·12, respectively and ,z = 0,02, 0·0 I, 0·04 and 0,05, Ann Clin Biochem 200I: 38 respectively). No obvious changes in bias as a function of each variable were evident in difference plots, and the above variables appear to have minimal influence on the reliability of ABL 735 whole blood bilirubin results.
DISCUSSION
Although most neonatal bilirubin measurements are made in the diagnostic laboratory, near-patient testing is an attractive option for many clinicians. In neonatal units, instruments that are easy to use and that provide important results quickly, with minimal sample requirements, have been widely accepted. A bilirubin module is now available for a blood gas analyser that can assess neonatal jaundice. The important question is whether results produced by this instrument are satisfactory for patient care. Guidelines for clinical intervention based on bilirubin concentration and clinical factors are widespread, and the American Academy of Pediatrics has produced guidelines for healthy neonates for phototherapy and exchange transfusion.P These guidelines assume that bilirubin can be measured 'accurately', and total error tolerances of ± 10% above 150Jlmol/L have been used as the criteria for acceptable results in an Australasian Neonatal Quality Assurance Programme. In the United States, Vreman et al. 13 have confirmed that even reputable laboratories can have difficulty measuring bilirubin, and Doumas and Eckfeldt have discussed the perennial problem of errors in the measurement of total bilirubin, which may include matrix effects for quality assurance materials."
With bilirubin being difficult to measure 'accurately' in plasma, the added complexity of measuring bilirubin in whole blood is substantial. Radiometer Copenhagen has developed an assay that makes bilirubin results available on a blood gas analyser in approximately 2 min using sample volumes as smalJas 35 JlL. With a sample volume of 55 jJL, blood gas and oximetry measurements are also available if required.
Because of the unacceptably large sample requirements for the reference method of Doumas, we assessed the reliability of the blood gas analyser bilirubin method using a routine method (with special calibration) that produces very similar results to the reference method and that only requires smalJ sample volumes. The most important conclusion from our study is that the blood gas analyser bilirubin module can produce results within ±25Jlmol/L of the results produced on the Hitachi analyser for most samples (95% confidence interval). This confidence interval includes precision errors from both analysers and the use of a representative MCHC on the blood gas analyser to calculate haematocrit, which is necessary to adjust for dilution by red cell fluid during ultrasonic haemolysis. For adults, where the 'accuracy' of bilirubin measurements is usually less demanding, the blood gas analyser bilirubin values were approximately 10% lower than those on the Hitachi.
Blood samples from some patients may have unusual spectra, which may compromise bilirubin results. We only saw one example of this during our study, and a suitable warning is required for questionable results in these circumstances. Drugs that displace bilirubin from albumin (e.g. sulphonamides) can theoretically influence results by modifying the absorbance spectrum of bilirubin. Such drugs are not used in the treatment of neonates to avoid kernicterus. Coloured substances (such as methylene blue) can also influence results, and Radiometer have carefully detailed interferences from coloured compounds.
'Photobilirubin', the light-induced conversion product of 'natural' bilirubin, is very rapidly removed, and bilirubin results should not be affected by phototherapy. Neonatal samples containing a very high proportion of conjugated bilirubin (very uncommon) may show the same underestimation seen in adults, although this requires further investigation.
Other issues important for near-patient testing, such as training, education, maintenance, sample integrity and recognition of unreliable results, are essential for this bilirubin module, as simplicity of operation can sometimes mask the potential for serious error. It is therefore important that clinical and laboratory staff cooperate closely to obtain the best performance from this new bilirubin assay.
Throughout the evaluation period, no major problems were experienced with the ABL 735 bilirubin method. Occasionally. the first sample after standby remained in the capillary when sampling was initiated. Whether this was due to a partial blockage or to other factors remains to be clarified. Long-term performance of the bilirubin module under routine operating conditions requires further assessment in a clinical environment. Until results from this study are confirmed in routine use, we recommend that bilirubin results be validated using a reliable laboratory method before important clinical decisions are made.
CONCLUSION
Providing this blood gas analyser bilirubin module is introduced conservatively for nearpatient testing, it has the potential to provide useful clinical information on the extent of neonatal jaundice.
